Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

NCT00864760
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

NCT01045096
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

NCT02255435
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years to 40 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Bioequivalence of Two Doses of Tafamidis

NCT04575116
View directory record Official record
Conditions
Healthy
Interventions
Tafamidis free acid tablet, Tafamidis meglumine capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 19, 2026, 5:23 PM EDT
Recruiting Phase 4 Interventional

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06577779
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Methylphenidate Hydrochloride Extended Release Capsule
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Effect of Daily CARDIO® Capsules Supplementation on Improved Sleep in Healthy, Urban-Dwelling Adults

NCT06768970
View directory record Official record
Conditions
Sleep, Pollution; Exposure, Cough
Interventions
CARDIO® salmon oil
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

NCT00152503
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (UCB44212)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

NCT02031666
View directory record Official record
Conditions
Healthy
Interventions
JNJ-56021927 capsule, JNJ-56021927 tablet
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

NCT04672460
View directory record Official record
Conditions
Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer
Interventions
TALZENNA capsule, Talazoparib soft gel capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • San Marcos, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional

A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients

NCT00002286
View directory record Official record
Conditions
HIV Infections, Psoriasis
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Image the Esophagus Using the OFDI Capsule

NCT02204150
View directory record Official record
Conditions
Barrett's Esophagus, Eosinophilic Esophagitis
Interventions
OFDI Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Posterior Capsular Injection With Femoral Nerve Block for Total Knee Arthroplasty

NCT02701296
View directory record Official record
Conditions
Posterior Knee Infiltration
Interventions
Ropivacaine with Epinephrine, Ropivacaine
Drug
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 19, 2026, 5:23 PM EDT
Not listed No phase listed Observational

Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests

NCT00258869
View directory record Official record
Conditions
Sepsis, Septicemia, Sepsis Syndrome, Shock, Septic, Community Acquired Pneumonia
Interventions
Not listed
Lead sponsor
National Center for Genome Resources
Other
Eligibility
6 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

NCT01153659
View directory record Official record
Conditions
Healthy
Interventions
E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

NCT00123461
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
Interventions
Hectorol (doxercalciferol capsules), 0.5mcg
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
17
States / cities
Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526
View directory record Official record
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

NCT00832052
View directory record Official record
Conditions
Healthy, Elderly
Interventions
PF-04447943
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 19, 2026, 5:23 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Proton Pump Inhibitors on Gut Microbiota Composition and Metabolites in Healthy Subjects Using CapScan

NCT07054593
View directory record Official record
Conditions
Healthy Subjects
Interventions
CapScan
Device
Lead sponsor
Envivo Bio Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

NCT00106821
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide Inhalation Powder
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Sepulveda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Iberdomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

NCT00637793
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
NGX267
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

NCT01101841
View directory record Official record
Conditions
Hot Flashes
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

NCT01308619
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Hot Springs, Arkansas • San Diego, California • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 19, 2026, 5:23 PM EDT